Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBIT Margin (2016 - 2025)

Seres Therapeutics' EBIT Margin history spans 10 years, with the latest figure at 6403.7% for Q3 2025.

  • For Q3 2025, EBIT Margin changed N/A year-over-year to 6403.7%; the TTM value through Sep 2025 reached 10673.89%, up 33169955.0%, while the annual FY2023 figure was 154.44%, 236961.0% up from the prior year.
  • EBIT Margin for Q3 2025 was 6403.7% at Seres Therapeutics, down from 4666.02% in the prior quarter.
  • Across five years, EBIT Margin topped out at 53.98% in Q3 2021 and bottomed at 197875.0% in Q4 2023.
  • The 5-year median for EBIT Margin is 2725.2% (2022), against an average of 17843.26%.
  • The largest annual shift saw EBIT Margin tumbled -19769746bps in 2023 before it skyrocketed 19320898bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 684.56% in 2021, then skyrocketed by 74bps to 177.54% in 2022, then tumbled by -111355bps to 197875.0% in 2023, then surged by 98bps to 4666.02% in 2024, then plummeted by -37bps to 6403.7% in 2025.
  • Per Business Quant, the three most recent readings for MCRB's EBIT Margin are 6403.7% (Q3 2025), 4666.02% (Q4 2024), and 197875.0% (Q4 2023).